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Abstract
Introduction: Although previous studies have reported etiologies, diagnostic strategies, and outcomes of acute
respiratory failure (ARF) in cancer patients, few studies investigated ARF in cancer patients presenting with diffuse
pulmonary infiltrates.
Methods: This was a retrospective observational study of 214 consecutive cancer patients with diffuse pulmonary
infiltrates on chest radiography admitted to the oncology medical intensive care unit for acute respiratory failure
between July 2009 and June 2011.
Results: After diagnostic investigations including bronchoalveolar lavage in 160 (75%) patients, transbronchial lung
biopsy in 75 (35%), and surgical lung biopsy in 6 (3%), the etiologies of diffuse pulmonary infiltrates causing ARF
were identified in 187 (87%) patients. The most common etiology was infection (138, 64%), followed by drug-
induced pneumonitis (13, 6%) and metastasis (12, 6%). Based on the etiologic diagnoses, therapies for diffuse
pulmonary infiltrates were subsequently modified in 99 (46%) patients. Diagnostic yield (46%, 62%, 85%, and 100%;
P for trend < 0.001) and frequency of therapeutic modifications (14%, 37%, 52%, and 100%; P for trend < 0.001)
were significantly increased with additional invasive tests. Patients with therapeutic modification had a 34% lower
in-hospital mortality rate than patients without therapeutic modification (38% versus 58%, P = 0.004) and a similar
difference in mortality rate was observed up to 90 days (55% versus 73%, Log-rank P = 0.004). After adjusting for
potential confounding factors, therapeutic modification was still significantly associated with reduced in-hospital
mortality (adjusted OR 0.509, 95% CI 0.281-0.920).
Conclusions: Invasive diagnostic tests, including lung biopsy, increased diagnostic yield and caused therapeutic
modification that was significantly associated with better outcomes for diffuse pulmonary infiltrates causing ARF in
cancer patients.
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Introduction
Recent advances in the early diagnosis and aggressive
management of cancer have improved long-term out-
comes in cancer patients [1]. However, a number of
patients with cancer may develop either malignancy-
related complications or treatment-associated side effects
requiring multidisciplinary care in an intensive care unit
(ICU) [2]. Acute respiratory failure (ARF) is the most
common cause for admission to the ICU in critically ill
cancer patients and is usually associated with a poor out-
come [3,4]. Although etiologies of respiratory failure in
cancer patients are diverse [5], the occurrence is often
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associated with development of diffuse pulmonary
infiltrates.
Various diagnostic strategies can be used to identify the
etiologies of ARF [5]. Consequently, definitive diagnosis
can be made in about 80% of cancer patients with ARF
[3,6,7]. However, most of these studies on etiologies of
ARF included all cancer patients with ARF, regardless of
extent of pulmonary infiltrates. Therefore, data for the
specific causes and outcomes of ARF presenting with dif-
fuse pulmonary infiltrates in cancer patients are scarce in
the literature. The objective of this study was to ascertain
the etiologies of, diagnostic strategies for, and outcomes of
diffuse pulmonary infiltrates causing ARF in cancer
patients.
Materials and methods
This was a retrospective observational study on the etiol-
ogy of diffuse pulmonary infiltrates causing ARF in cancer
patients admitted to the oncology medical ICU of Sam-
sung Comprehensive Cancer Center of Samsung Medical
Center (a 1,960-bed, university-affiliated, tertiary referral
hospital in Seoul, South Korea) between July 2009 and
June 2011; the ICU has 14 beds and provides care for
approximately 350 critically ill cancer patients per year.
The study was approved by the Institutional Review Board
of Samsung Medical Center to review and publish infor-
mation obtained from the patients’ records. Informed
consent was waived because of the retrospective nature of
the study.
Study population
Over the study period, a total of 583 patients with cancer
were admitted to the oncology medical ICU. Of these
patients, a total of 214 consecutive cancer patients with
ARF and diffuse pulmonary infiltrates on chest radiogra-
phy were included in the study. There was no patient with
more than one ICU admission over the study period. ARF
was defined as the presence of respiratory distress symp-
toms such as tachypnea (respiration rate >30/min) with
either need for ventilator support or an arterial partial
pressure of oxygen (PaO2)/fraction of inspired oxygen
(FiO2) ratio (PF ratio) <300. Diffuse pulmonary infiltrates
were defined as diffuse opacities involving all four
quadrants of lung on chest radiography [8].
Diagnostic evaluations
According to our diagnostic strategy for pulmonary infec-
tious disease in cancer patients with diffuse pulmonary
infiltrates, non-invasive tests including blood cultures;
examination of the sputum for bacteria, mycobacteria, and
fungi; urine tests for antigens of Streptococcus pneumoniae
and Legionella pneumophila; and serologic tests for Myco-
plasma were performed routinely. Blood tests for cytome-
galovirus (CMV) antigen [9] and an Aspergillus
galactomannan assay [10] were performed when there was
a high suspicion of any of these pathogens. In addition,
chest computed tomography (CT) scans were also
performed to differentiate etiologies of diffuse pulmonary
infiltrates if possible. For etiologic evaluation of acute
respiratory failure from causes other than pulmonary dis-
ease, echocardiography, and blood tests for cardiac
markers were performed in the ICU.
Bronchoaveolar lavage (BAL), transbronchial lung
biopsy (TBLB), and surgical lung biopsy (SLB) were per-
formed based on a joint decision of attending physicians
and intensivists. BAL was performed using the standard
technique as previously described [11]. BAL fluid samples
were stained using Gram and Ziehl-Neelsen methods and
then cultured for bacteria, mycobacteria, and fungi. Multi-
plex nested polymerase chain reaction (PCR) assays were
used to detect influenza viruses A and B; parainfluenza
viruses 1, 2, and 3; respiratory syncytial virus; and adeno-
virus [12]. Quantification of CMV DNA in BAL fluid was
also performed using quantitative real-time PCR [13]. In
addition, CMV and adenovirus were cultured using
standard techniques. Calcoflour white stain and Grocott-
Gomori methenamine silver stain were used to detect
Pneumocystis jiroveci in BAL fluid [14]. TBLB and SLB
were performed at the segment exhibiting the most severe
abnormalities by chest CT scan. Specimens were analyzed
by cultures, staining, and histologic testing.
Definitions
Diagnoses were based on clinical, radiologic, microbiolo-
gic, and histopathologic findings [3] and were thoroughly
reviewed by two of the authors (HY and KJ). Differences
in observed findings were resolved by consensus. All diag-
noses were classified as definite, probable, or non-diagnos-
tic as follows. Definite diagnosis of bacterial pneumonia
was defined as the pathogen being identified in BAL fluid
in an amount >104 CFU/mL or the same pathogen being
isolated from respiratory specimens and blood cultures.
Probable diagnosis of bacterial pneumonia was defined as
improvement of the patient’s clinical conditions after anti-
biotic treatment even though the pathogen was not
isolated from a respiratory specimen. Definite viral pneu-
monia was defined as observation of the cytopathologic
effect of a virus in histopathology [15]. Probable viral
pneumonia was defined as recovery of a virus in BAL fluid
or nasopharyngeal specimens from a patient with clinical
features consistent with viral pneumonia. However, a posi-
tive CMV PCR test or antigenemia was not sufficient for
diagnosis of CMV pneumonia [3]. Pulmonary aspergillosis
was diagnosed according to recently developed criteria for
invasive fungal disease [16]. The diagnosis of P. jiroveci
pneumonia was made by identification of P. jiroveci from
a clinically relevant specimen of sputum, BAL fluid or
lung tissue [17]. Cardiogenic pulmonary edema was
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diagnosed when echocardiography and biomarkers showed
cardiac dysfunction in patients with a compatible clinical
picture [18]. Diffuse alveolar hemorrhage (DAH) asso-
ciated with an underlying malignancy was diagnosed using
previously reported criteria [19]. However, alveolar hemor-
rhage was considered to be a manifestation of lung disease
but not a cause of ARF, except in patients with no BAL
evidence of infection and no evidence of congestive heart
failure [19,20]. Drug-induced pneumonitis was defined as
combination of the presence of a compatible clinical pat-
tern, drug that is a known or suspected offender, and the
exclusion of infection or pulmonary involvement from the
underlying malignancy [21]. As this study included only
patients with malignancies, other definitions associated
with cancer status were defined by previously reported
definitions [22-24]. Patients experiencing a relapse in their
malignancies following intensive front-line chemotherapy
or who failed to respond to initial chemotherapy were
considered to be in a relapsed/refractory status [22]. The
extensiveness of malignancy was classified according to
the extent of the tumor and major organ involvement, as
reported previously [22,23]. Disease extent was evaluated
as extensive disease and/or major organ involvement.
Extensive disease was defined as stage III or IV for lym-
phoma; metastatic or locally extensive disease for solid
malignancies; and >80% blasts in bone marrow, >25,000
blasts/μL in peripheral blood, or the need for leukapher-
esis for hematological malignancies [22]. Major organ
involvement was defined as a pathologically confirmed or
radiologically suspected invasion of the brain, heart, lung,
liver, or kidney [24]. Neutropenia was defined by an abso-
lute neutrophil count (ANC) <0.5×103/μL [25,26]. Thera-
peutic modification was defined as the addition, change of
class, or withdrawal of antimicrobial agents, chemother-
apy, or steroids according to identification of an etiology
or exclusion of a presumptive diagnosis [27].
Data collection
The following clinical data on ICU admission were
extracted from the medical records: age, gender, type of
malignancy, disease extent, recent chemotherapy adminis-
tration, need for mechanical ventilation, need for renal
replacement, or need for vasopressor therapy. Severity of
illness was assessed by the Simplified Acute Physiology
Score 3 (SAPS 3) [28] and Sequential Organ Failure
Assessment (SOFA) [29]. Finally, we documented out-
comes of cancer patients with ARF with diffuse pulmonary
infiltrates including length of stays in ICU and hospital,
ICU and hospital mortality, and 90-day mortality.
Statistical analysis
Data are reported as numbers (percentages) for categori-
cal variables and as medians with interquartile ranges
(IQR, 25th-75th percentiles) for continuous variables.
Continuous variables were compared using the Mann-
Whitney U test and categorical variables using the
Chi-square test or Fisher’s exact test. To assess whether
there was an association between addition of diagnostic
procedures and identification rate of etiologies, the
Mantel-Haenszel test was used to examine trends of
diagnostic rate across additional diagnostic procedures.
The baseline characteristics, frequency of identified etio-
logic diagnosis and therapeutic modification based on the
diagnosis were then compared between survivors and
non-survivors to evaluate the effect of therapeutic modifi-
cation on outcome. A multiple logistic regression model
was used to adjust for potential confounding factors in the
association between therapeutic modification and in-hos-
pital mortality, as measured by the estimated odds ratio
(OR) with the 95% confidence interval (CI). Variables with
a P value < 0.20 in the univariate analysis were entered
into a multiple logistic regression model where in-hospital
mortality was the outcome variable of interest. The Hos-
mer-Lemeshow test was used to check the goodness of fit
of the logistic regression. Discrimination capability was
evaluated by determination of the area under the receiver
operating characteristic (ROC) curve. To reduce the risk
of multicollinearity, only one variable from a group of
closely correlated variables was a candidate for inclusion
in the final model. Kaplan-Meier estimation was used to
determine the 90-day survival curves for therapeutic modi-
fication, which were then compared using the log-rank
test for survival data.
All tests were two-sided, and a P value < 0.05 was
considered significant. Data were analyzed using IBM
SPSS Statistics 19.0 (IBM, Chicago, IL, USA).
Results
The baseline clinical characteristics of the 214 cancer
patients (116 with hematologic malignancies and 98 with
solid tumors) admitted to the oncology medical ICU for
ARF with diffuse pulmonary infiltrates on chest radiogra-
phy are summarized in Table 1. Eighty-nine (42%) patients
had received cancer chemotherapy within 4 weeks prior to
ICU admission: median time from chemotherapy to ICU
admission was 15 (11-20) days. On ICU admission, all
patients had hypoxemia requiring oxygen therapy and 109
(51%) patients were mechanically ventilated (98 patients
with invasive mechanical ventilation and 11 patients with
non-invasive ventilation). A total of 210 (98%) patients
were receiving one or more antibacterial agents at the
time of ICU admission.
All patients underwent noninvasive tests including
chest radiography and microbiologic tests of blood and
sputum (Table 2). Fiberoptic bronchoscopy with BAL
was performed in 160 (75%) patients within a median
time of 16 h (range, 2-27 h) after ICU admission. Of
these patients, mechanical ventilator support was
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Table 1 Baseline characteristics of 214 cancer patients with acute respiratory failure and diffuse pulmonary infiltrates
on chest radiography.
Total (n = 214) Hematologic (n = 115,
54%)
Solid (n = 99,
46%)
P
value
Age (years) 60 (51-68) 56 (44-67) 62 (56-69) 0.002
Gender (male) 144 (67) 77 (67) 67 (68) 0.911
Co-morbidities 111 (52) 59 (51) 52 (53) 0.859
Cardiovascular 40 19 21
Respiratory 25 11 14
Hepatic 10 4 6
Renal 4 3 1
Diabetes 2 2 0
Othersa 15 12 3
ECOG performance status (3 or more) 61 (28) 35 (30) 26 (26) 0.500
Type of malignancy
Solid 98 (46)
Hematologic 116 (54)
Status of malignancy
Relapsed/refractory 64 (30) 34 (30) 30 (30) 0.906
Extensive disease or major organ involvement 151 (71) 66 (58) 85 (86) <0.001
Stem cell transplantation 28 (13) 28 (24) 0
Allogenic 11 11
Autologous 17 17
Duration of malignancy, months 8.2 (2.9-19.4) 7.4 (2.6-18.2) 8.5 (3.1-24.0) 0.154
Clinical status on ICU admission
Antibacterial agents 210 (98) 115 (100) 95 (96) 0.044
Recent chemotherapy prior to ICU admission within 4
weeks
89 (42) 45 (39) 44 (44) 0.487
Need for mechanical ventilationb 109 (51) 43 (37) 66 (67) <0.001
Need for vasopressor support 52 (24) 28 (24) 24 (24) 0.986
Need for renal replacement therapy 19 (9) 16 (14) 3 (3) 0.005
Laboratory findings
WBC,/μL 6,305 (2,250-
12,378)
3,030 (730-7,280) 10,220 (5,330-
15,670)
<0.001
ANC,/μL 3,970 (995-8,545) 1,700 (240-4,570) 7,520 (3380-12,680) <0.001
Neutropenia (ANC <500/μL) 40 (18) 32 (28) 8 (8) <0.001
Platelet, 103/μL 112.5 (29.0-234.8) 35.0 (16.0-117.0) 187.0 (116.0-271.0) <0.001
CRP, mg/dL 14.8 (7.4-22.3) 12.1 (5.5-19.8) 16.2 (10.4-24.0) 0.003
Procalcitonin, ng/mL 0.65 (0.19-2.85) 0.72 (0.19-3.70) 0.56 (0.17-2.29) 0.443
pH 7.444 (7.375-7.474) 7.452 (7.400-7.483) 7.433 (7.362-7.465) 0.017
NT-proBNP, pg/mL 1392 (273-4796) 2,108 (445-8,780) 940 (239 - 3424) 0.035
PF ratio 145 (105-214) 160 (109-234) 134 (101 - 181) 0.075
Severity of illness
SAPS 3 (points) 61 (50-75) 65 (52-78) 58 (48-66) 0.002
SOFA score (points) 6 (3-8) 6 (4-9) 5 (3-8) 0.013
Length of stay in ICU (days) 6 (3-13) 5 (2-10) 7 (3-16) 0.012
Length of stay in hospital (days) 26 (15-44) 31 (17-59) 21 (12-34) 0.002
ICU mortality 64 (30) 33 (29) 31 (31) 0.765
In-hospital mortality 105 (49) 55 (48) 50 (51) 0.784
90-day mortality 138 (65) 68 (59) 70 (71) 0.087
aChronic hepatitis (n = 4), graft-versus-host disease (n = 3), Grave’s disease (n = 2), Parkinson’s disease (n = 2), systemic lupus erythematosus (n = 2), aplastic
anemia (n = 1), adrenal insufficiency (n = 1).
bNumber includes both invasive and non-invasive mechanical ventilation.
ANC, absolute neutrophil count; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; ICU, intensive care unit; IQR, interquartile range; NT-proBNP,
N-terminal pro-brain natriuretic peptide; PF ratio, arterial partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio; SAPS 3, Simplified Acute
Physiology Score 3; SOFA, Sequential Organ Failure Assessment; WBC, white blood cell.
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required during the procedures in 78 (49%) patients
(invasive ventilation in 70 and non-invasive ventilation
in 8). TBLBs were performed simultaneously with BAL
in 75 (35%) patients. In six (3%) patients, SLB under
general anesthesia was performed. Procedure-related
complications were observed in 25 (16%) for broncho-
scopic BAL ± TBLB and one (17%) for SLB. Intubation
was required within 24 h after bronchoscopy in 10 of 90
(11%) patients who were not intubated before the proce-
dures. Pneumothorax necessitating tube thoracostomy
occurred in 12 patients, and major bleeding developed
in one patient after TBLB. Prolonged air-leakage devel-
oped in one patient who underwent SLB. However,
there were no cases of procedure-related death.
After vigorous diagnostic investigations, the etiologies
of diffuse pulmonary infiltrates causing ARF in cancer
patients were identified in 187 (87%) patient: definite
diagnosis in 82 (38%) and probable diagnosis in 105
(49%) (Table 3). The most common infectious etiology
was bacterial pneumonia in 63 (29%) patients, followed
by viral pneumonia in 39 (18%), fungal pneumonia in 19
(9%), P. jiroveci pneumonia in 14 (7%), and tuberculosis
in three (1%) patients (Table 3). Common bacterial
pathogen isolated from patients with definite bacterial
pneumonia were Staphylococcus aureus (8, 29%), Kleb-
siella pneumonia (6, 21%), Pseudomonas aeruginosa (4,
14%), and Acinetobacter baumannii (4, 14%). Common
viral pathogens were CMV (14, 36%), influenza A (8,
21%), adenovirus (7, 18%), and respiratory syncytial
virus (6, 15%). Most fungal pneumonia was invasive pul-
monary aspergillosis except for mucormycosis in one
patient and disseminated candidiasis involving the lung
in another patient. In cases of non-infectious etiologies,
pulmonary metastasis and diffuse alveolar hemorrhage
were proven in 12 (6%) and eight (4%) patients, respec-
tively. One patient was suspected of Lipiodol embolism
with lung injury after transarterial chemoembolization
for hepatocellular carcinoma. One patient with AML in
whom diffuse infiltrates developed 8 days after the use
of all-transretinoid acid (ATRA) was diagnosed clinically
with ATRA syndrome.
Out of all 214 patients, the etiologies of diffuse pulmon-
ary infiltrates causing ARF could be identified in only 99
(46%) patients through non-invasive tests. BAL exclusively
provided etiologic diagnoses in 57 (36%) out of 160
patients who received BAL in addition to non-invasive
Table 2 Non-invasive and invasive diagnostic
investigations performed.
Patients, n (%)
Non-invasive tests
Blood cultures for bacteria 214 (100)
Sputum examination for bacteria 214 (100)
Sputum examination for fungi 214 (100)
Sputum examination for mycobacteria 210 (98)
Urine Streptococcus pneumonia antigen 186 (87)
Urine Legionella pneumophila antigen 108 (50)
Serum mycoplasma antibody 159 (74)
Serum Aspergillus galactomannan assay 95 (44)
CMV antigenemia 94 (44)
Chest CT scans 209 (98)
Echocardiography 24 (11)
Invasive tests
Fiberoptic bronchoscopy 160 (75)
BALa 160
TBLB 75
Surgical lung biopsy 6 (3)
aNumber includes the number of patients who received concomitant TBLB.
BAL, bronchoalveolar lavage; CMV, cytomegalovirus; CT, computed
tomography; TBLB, transbronchial lung biopsy
Table 3 Etiologies of diffuse pulmonary infiltrates causing acute respiratory failure in cancer patients.
Etiologies Diagnostic probability (n = 214) Hematologic (n = 115) Solid (n = 99)
Total Definite Probable Definite Probable Definite Probable
Infectious etiologies 138 (64) 58 (27) 80 (37) 31 (27) 51 (44) 27 (27) 29 (29)
Bacterial 63 (29) 28 (13) 35 (16) 14 (12) 15 (13) 14 (14) 20 (20)
Viral 39 (18) 9 (4) 30 (14) 4 (3) 23 (20) 5 (5) 7 (7)
Fungal 19 (9) 4 (2) 15 (7) 2 (2) 13 (11) 2 (2) 2 (2)
P. jiroveci 14 (7) 14 (7) 0 10 (9) 0 4 (5) 0
Tuberculosis 3 (1) 3 (1) 0 1 (1) 0 2 (2) 0
Non-infectious etiologies 49 (23) 24 (11) 25 (12) 10 (9) 8 (7) 14 (14) 17 (17)
Metastasis 12 (6) 12 (6) 0 1 (1) 0 11 (11) 0
Diffuse alveolar hemorrhage 8 (4) 8 (4) 0 6 (5) 0 2 (2) 0
Cardiogenic pulmonary edema 10 (5) 3 (1) 7 (3) 2 (2) 5 (4) 1 (1) 2 (2)
Drugs 13 (6) 0 13 (6) 0 2 (2) 0 11 (11)
Othersa 6 (3)a 1 (0) 5 (2) 1 (1) 1 (1) 0 4 (4)
Total 187 (87) 82 (38) 105 (49) 41 (36) 59 (51) 42 (42) 46 (47)
aRadiation pneumonitis (n = 3), lipiodol embolism with lung injury (n = 1), pulmonary alveolar proteinosis (n = 1), all-transretinoic-acid syndrome (n = 1).
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tests and TBLB in combination with BAL and non-inva-
sive tests additionally provided etiologic diagnoses in 27
(36%) patients. Etiologies were identified in all six patients
with SLB providing a diagnosis exclusively in three (50%)
patients. Diagnostic yield significantly increased with addi-
tional invasive tests (P < 0.001, test for trends) (Figure 1A).
Based on the etiologic diagnoses, therapies for diffuse pul-
monary infiltrates were subsequently modified in 99 (46%)
patients. These modifications included initiation (n = 59),
change (n = 9), or discontinuation (n = 15) of antimicro-
bial agents in 83 (84%) patients, initiation of corticoster-
oids in 14 (14%) patients, and initiation of chemotherapy
in two (2%) patients. In addition, end-of-life decision was
made based on the identified etiologies of diffuse pulmon-
ary infiltrates in 10 patients. Frequencies of therapeutic
modification based on the results from non-invasive tests
and invasive tests were also evaluated across additional
diagnostic tests. The frequency of therapeutic modification
significantly increased with additional invasive tests (P <
0.001, test for trends) (Figure 1B).
Sixty-four (30%) patients died in the ICU after a median
time of 6 days (range, 3-13 days). One hundred-five (49%)
patients died during hospitalization and the median length
of stay in the hospital was 26 days (range, 15-44). The 90-
day mortality after ICU admission was 65%. Univariate
comparisons of baseline characteristics, identified etiologic
diagnosis, and therapeutic modification between survivors
(n = 109, 51%) and non-survivors (n = 105, 49%) are
presented in Table 4. Although there was no difference in
the number of patients whose etiologic diagnoses were
established (51% vs. 49%, P = 0.757), therapeutic modifica-
tion based on the diagnosis of diffuse pulmonary infiltrates
causing ARF was significantly associated with lower in-
hospital mortality (62% vs. 38%, P = 0.004). Patients with
therapeutic modification had a 34% lower in-hospital mor-
tality rate than patients without therapeutic modification
(38% vs. 58%, P = 0.004) and a similar difference in
mortality rate was observed up to 90 days (P = 0.004,
Figure 2). This finding was similar even after exclusion of
10 patients in whom the end-of-life decision was made
based on the etiologic diagnosis from diagnostic strategies
(see Additional file 1, Table S2/Table S3/Figure S1). After
adjusting for potential confounding factors, therapeutic
modification was still significantly associated with in-hos-
pital mortality (adjusted OR 0.509, 95% CI 0.281-0.920;
Hosmer-Lemeshow goodness-of-fit test, P = 0.325). The
estimated area under the ROC curve for the therapeutic
modification was 0.727 (95% CI, 0.659-0.794) (Table 5).
Comparison of baseline characteristics according to
type of malignancy is summarized in Table 1. Although
extensive or major organ involvement was less frequent
in patients with hematologic malignancy, severity of
illness assessed by SAPS 3 and SOFA score was higher
in patients with hematologic malignancy compared to
patients with solid tumor. Identified etiologies of diffuse
pulmonary infiltrates causing ARF are listed in Table 2.
Although there was no difference in the number of
patients whose etiologic diagnoses were established, the
frequency of therapeutic modification based on the
identified etiologies was higher in patients with hemato-
logic malignancy compared to patients with solid tumor
(Table 6). In addition, therapeutic modification based on
the diagnosis of diffuse pulmonary infiltrates causing
ARF was significantly associated with lower 90-day mor-
tality in patients with hematologic malignancy (P =
0.009, Figure 3A). However, it was not statistically sig-
nificant in patients with solid tumor (P = 0.274,
Figure 3B).
Discussion
This study evaluated the etiologies of and diagnostic stra-
tegies for diffuse pulmonary infiltrates causing ARF in
cancer patients admitted to the ICU. The results of our
retrospective cohort study indicated that the etiologies of
Figure 1 Contributions of non-invasive and invasive tests to the diagnosis and therapeutic modifications of diffuse pulmonary
infiltrates causing acute respiratory failure in cancer patients. (A) Comparison of diagnostic yields across additional invasive tests in
combination with non-invasive tests (P < 0.001). (B) Comparison of frequencies of therapeutic modifications across additional invasive tests in
combination with noninvasive tests (P < 0.001).
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diffuse pulmonary infiltrates causing ARF in cancer
patients could be identified in 87% of the patients after
non-invasive and invasive investigations including lung
biopsy. Based on the etiologic diagnoses, therapies for
diffuse pulmonary infiltrates were subsequently modified
in 46% of the patients. Diagnostic yield and frequency of
therapeutic modification were significantly increased with
the addition of invasive tests to non-invasive tests. Addi-
tionally, we found that therapeutic modification based on
the etiologic diagnosis was significantly associated with
lower in-hospital mortality in cancer patients with diffuse
pulmonary infiltrates causing ARF.
The etiologic diagnosis of diffuse pulmonary infiltrates
in cancer patients poses special challenges to the inten-
sivist. Previous studies on the impact of diagnostic
investigations including fiberoptic bronchoscopy found
that the etiologic diagnoses could be identified in
approximately 80% of cancer patients with ARF [3,6,7].
However, these studies could not report the etiologies of
diffuse pulmonary infiltrates causing ARF in cancer
patients. In addition, lung biopsy was not included in
the diagnostic strategies. In this study, we included can-
cer patients with diffuse pulmonary infiltrates on chest
radiography and performed lung biopsies in approxi-
mately 40% of the patients. As a result, bacterial pneu-
monia was found to be the most common cause of ARF
in cancer patients with diffuse pulmonary infiltrates,
consistent with that mentioned in previous reports
[3,6,7]. However, viral pneumonia was also common in
our cohort, which differs from previous studies. This
could be associated with different nature of pulmonary
infiltrates in this study and might be attributed to the
Figure 2 Kaplan-Meier survival analysis comparing patients
with therapeutic modification (n = 99) or no modification (n =
115) for etiologies of diffuse pulmonary infiltrates causing
acute respiratory failure (P = 0.004, log-rank test).
Table 4 Comparisons of baseline characteristics between survivors and non-survivors.
Survivor (n = 109, 51%) Non-survivor (n = 105, 49%) Odds ratio (95% CI) P value
Age (years) 59 (51-66) 62 (51-69) 1.007 (0.998-1.027) 0.477
Gender (male) 71/144 (49) 73/144 (51) 1.221 (0.689-2.165) 0.494
Co-morbidity 51/111 (46) 60/111 (54) 1.516 (0.884-2.600) 0.130
Type of malignancy
Hematology 60/115 (52) 55/115 (48) 0.898 (0.525-1.538) 0.696
ECOG performance status (3 or more) 22/61 (36) 39/61 (64) 2.337 (1.266-4.313) 0.006
Status of malignancy
Relapsed/refractory 24/64 (38) 40/64 (63) 2.179 (1.196-3.973) 0.010
Extensive or major organ involvement 76/151 (50) 75/151 (50) 1.086 (0.603-1.955) 0.785
Stem cell transplantation 9/28 (32) 19/28 (68) 2.455 (1.056-5.708) 0.033
Duration of malignancy, months 9.8 (3.1-22.5) 6.9 (2.7-18.4) 0.997 (0.989-1.005) 0.486
Clinical status on ICU admission
Recent chemotherapy 88/182 (48) 94/182 (52) 2.039 (0.930-4.472) 0.071
Need for mechanical ventilationa 44/109 (40) 65.109 (60) 2.401 (1.386-4.157) 0.002
Need for vasopressor support 20/52 (39) 32/52 (62) 1.951 (1.030-3.695) 0.039
Need for renal replacement therapy 8/19 (42) 11/19 (58) 1.477 (0.570-3.832) 0.42
Neutropenia 12/40 (30) 28/40 (70) 2.939 (1.403-6.157) 0.003
Severity of illness
SAPS 3 (points) 59 (50-72) 64 (50-76) 1.016 (1.001 - 1.032) 0.0420
SOFA score (points) 5 (3-7) 7 (4-9) 1.125 (1.033 - 1.226) 0.007
Identified etiology 96/187 (51) 91/187 (49) 0.880 (0.393 - 1.974) 0.757
Therapeutic modification 61/99 (62) 38/99 (38) 0.446 (0.258 - 0.773) 0.004
aNumber includes both invasive and non-invasive mechanical ventilation.
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; ICU, intensive care unit; SAPS 3, Simplified Acute Physiology Score 3; SOFA, Sequential Organ
Failure Assessment.
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fact that lung biopsy was performed. Confirmative diag-
nosis of viral pneumonia in this study was made by
cytopathologic effect of the virus seen on histopathol-
ogy. From the results of etiologic diagnosis determined
by lung biopsy in bone marrow transplant recipients
with pulmonary infiltrates [8], viral pneumonia was a
major infectious etiology.
Both invasive and non-invasive diagnostic strategies can
be used to identify the cause of pulmonary infiltrates in
cancer patients with acute respiratory failure [5]. The inva-
sive strategy relies on fiberoptic bronchoscopy with BAL
which remains the cornerstone of the diagnosis of
pulmonary infiltrate in nonhypoxemic cancer patients.
However, previous studies on the additional diagnostic
yield of invasive techniques showed that bronchoscopy
with BAL establishes the diagnosis in half of the patients
at best and leads to therapeutic modification in only one-
third of patients [13,30]. In addition, recent multicenter
cohort and randomized controlled studies found that the
additional diagnostic yield of BAL in combination with
noninvasive tests is relatively low [6,7]. In this study, BAL
exclusively provided etiologic diagnoses in one-third of
patients who underwent BAL in addition to non-invasive
tests. However, TBLB simultaneously performed with BAL
increased diagnostic yield, consistent with previous reports
on the diagnostic yield of TBLB added to BAL in
immunocompromised patients with pulmonary infiltrates
[31,32]. Moreover, SLB also provided additional diagnostic
yield even though a small number of patients was
included. Nevertheless, invasive diagnostic procedures
have potential risk of complications. In our study, proce-
dure-related complications were observed in about 16% of
patients. However, there was no procedure-related death
and no difference in complication-associated outcomes
between patients who underwent invasive diagnostic
procedures with and without lung biopsy (see Additional
file 1, Table S4). Therefore, we suggest that lung biopsy in
addition to BAL could be considered as a potential inva-
sive diagnostic strategy to identify the cause of diffuse
pulmonary infiltrates in cancer patients, if feasible. How-
ever, the risk-benefit implications of these procedures
need to be further evaluated.
Identifying the cause of pulmonary infiltrates with inva-
sive test as well as non-invasive tests is associated with
better outcome in hematologic patients with ARF [27,33].
This could be explained by the fact that having a specific
diagnosis leads to receiving the appropriate treatment and
could eliminate the toxicity of unnecessary medications.
However, a recent multicenter cohort study could not find
an association between specific diagnoses and outcome in
cancer patient with ARF [6]. These counterintuitive results
may be explained in terms of therapeutic modification
based on the results from a diagnostic strategy [30]. In the
present study, in-hospital (P = 0.757) and 90-day (P =
0.860) mortalities were not different between the patients
with and without a specific diagnosis of diffuse pulmonary
infiltrates. However, based on the results of diagnostic
tests, therapies for diffuse pulmonary infiltrates were
subsequently modified in half of the patients and resulted
in significantly better outcomes, consistent with results
from a previous study [30]. In addition, similar finding was
observed in the subgroup analysis according to type of
Table 5 Risk factors associated with in-hospital mortality
by multiple logistic regression analysis.
Adjusted OR (95% CI) P value
Therapeutic modification 0.509 (0.281-0.920) 0.025
ECOG performance status (3 or more) 1.973 (1.027-3.791) 0.041
Stem cell transplantation 3.041 (1.242-7.447) 0.015
Need for mechanical ventilation 2.374 (1.320-4.270) 0.004
Neutropenia 2.464 (1.133-5.358) 0.023
CI, confidence interval; OR, odds ratio.
Table 6 Therapeutic modification and outcomes of patients with hematologic malignancies and solid tumors.
Hematologic (n = 115, 54%) Solid (n = 99, 46%) P value
Therapeutic modification 62 (54) 37 (37) 0.016
Initiation of antimicrobial agents 40 19
Change of antimicrobial agents 8 1
Withdrawal of antimicrobial agents 10 5
Initiation of steroid 3 11
Initiation of chemotherapy 1 1
End-of-life decision 0 10 (10) <0.001
Outcomes
ICU mortality 33 (29) 31 (31) 0.677
Length of stay in ICU (days) 5 (2-10) 7 (3-16) 0.008
In-hospital mortality 55 (48) 50 (51) 0.696
Length of stay in hospital (days) 31 (17-59) 22 (12-34) 0.004
90-day mortality 68 (59) 70 (71) 0.078
ICU, intensive care units.
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malignancy (Figure 3A/Figure 3B). Although it is possible
that the better outcome was related only to the nature of
the causes of diffuse pulmonary infiltrates itself or other
risk factors, our data suggest that the therapeutic modifi-
cations made on a specific diagnosis would be more
important, than making a specific diagnosis itself with
invasive tests, in the management of cancer patients with
diffuse pulmonary infiltrates causing ARF.
To fully appreciate these results, the limitations of this
study must be acknowledged. First, given its retrospective
nature, selection bias may have influenced the signifi-
cance of our findings. Furthermore, our study was con-
ducted at a single institution with a specialized ICU for
critically ill cancer patients, which may limit the general-
izability of our findings to other centers in which no
experienced intensivists are available for oncological criti-
cal care. Second, the decision to perform bronchoscopic
BAL and TBLB were at the physician’s discretion, and
not all non-invasive tests were performed routinely.
More severely ill patients might not have undergone
invasive tests, especially TBLB or SLB. However, we
focused on the influence of therapeutic modification
rather than invasive procedures on outcome. In addition,
adjusted multivariable analysis served to minimize the
potential for selection bias. However, the potential for
bias due to an unmeasured confounder remains.
Conclusions
The results of this study demonstrated a significant
association between invasive diagnostic tests including
lung biopsy and increased diagnostic yield and therapeu-
tic modification which resulted in better outcomes in
cancer patients with diffuse pulmonary infiltrates. This
finding highlights the importance of the therapeutic
modification based on the results of invasive diagnostic
tests in the management for diffuse pulmonary infil-
trates causing ARF in cancer patients. However, this
observation needs to be further evaluated by a multicen-
ter, prospective study.
Key messages
• The etiologies of diffuse pulmonary infiltrates caus-
ing acute respiratory failure in cancer patients could
be identified in the majority of the patients.
• Invasive tests including bronchoalveolar lavage and
transbronchial lung biopsy in combination with non-
invasive tests additionally provided etiologic diag-
noses of diffuse pulmonary infiltrates.
• Therapeutic modification based on the etiologic
diagnosis was significantly associated with lower in-
hospital mortality in cancer patients with diffuse pul-
monary infiltrates.
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Figure 3 Kaplan-Meier survival analysis comparing patients with therapeutic modification or no modification for etiologies of diffuse
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